Interestingly, our previous research revealed that baicalin would potentially be an effective therapeutic agent for hyperandrogenism in PCOS by inhibiting the recruitment of GATA1 to the HSD3B2 promoter in ovarian tissue [19]. Here, HSD3B2 is linked to polycystic ovary syndrome.